EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Takeshi Miyatsuka iD, James Brash, Eleanor Davies iD, Elisabeth de Laguiche iD, Dorte Vistisen iD, Can Yin iD, Atif Adam iD

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6291-6300

DOI: 10.1111/dom.70812 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.05.2026. Verfasst von Takeshi Miyatsuka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Drug Monitoring. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan. Materials and Methods This retrospective, observational cohort study used DeSC‐IQVIA Integrated claims data from Japan to identify adults (aged ≥ 18 years) with confirmed T2D and ≥ 1 prescription for a GLP‐1 RA (with predefined basal insulin persistence window) or an FRC during October 2019 to September 2023. Study index was date of first GLP‐1 RA or FRC prescription; follow‐up was 365 days. The primary objective was to evaluate adherence to and persistence with free combination therapy versus FRC therapy.

Results

Age (mean [standard deviation]) at index was statistically significantly higher in the free combination group (67.0 [13.85] years, n = 2063) than in the FRC group (65.7 [13.85] years, n = 2386) ( p = 0.002). Odds of optimal adherence at end of follow‐up were statistically significantly higher with FRC therapy than with free combination therapy (adjusted odds ratio [95% confidence interval]: 1.96 [1.73–2.23]; p < 0.001). Risk of discontinuation by end of follow‐up was statistically significantly lower with FRC therapy than with free combination therapy (adjusted hazard ratio [95% confidence interval]: 0.66 [0.61–0.71]; p < 0.001). Adherence and persistence findings were similar in elderly individuals.

Conclusions

In this real‐world, adult population with T2D in Japan, FRC therapy was associated with improved adherence and persistence versus free combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsDrug MonitoringInsulinHumansJapanRetrospective StudiesFemaleAgedMiddle AgedMaleDrug Therapy, CombinationDatabases, FactualDrug CombinationsEast Asian People

Stichwörter der Autor:innen

GLP‐1 analoguebasal insulindatabase researchfixed‐ratio combinationtype 2 diabetes

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsInsulinDrug Combinations

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Metabolism, Kitasato University School of Medicine, Sagamihara, Japan.
  • IQVIA Inc, London, UK.
  • Novo Nordisk A/S, Søborg, Denmark.

ORCID-Profile: Takeshi Miyatsuka, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam

Förderung

  • Novo Nordisk

Zitieren

APA

Miyatsuka, T., Brash, J., Davies, E., de Laguiche, E., Vistisen, D., Yin, C., & Adam, A. (2026). Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study. Diabetes, Obesity and Metabolism, 28(7), 6291-6300. https://doi.org/10.1111/dom.70812

Vancouver

Miyatsuka T, Brash J, Davies E, de Laguiche E, Vistisen D, Yin C, et al. Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study. Diabetes, Obesity and Metabolism. 2026;28(7):6291-6300. doi:10.1111/dom.70812

BibTeX
@article{Miyatsuka2026,
  author = {Miyatsuka, Takeshi and Brash, James and Davies, Eleanor and de Laguiche, Elisabeth and Vistisen, Dorte and Yin, Can and Adam, Atif},
  title = {Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6291--6300},
  doi = {10.1111/dom.70812}
}
Kostenlos starten →